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Plasma is the component ofblood from which lead is free to cross ce}l membranes and cause
organ toxicity. Plasma lead levels, h -wever,are extremely low nd difficlt t measure. Urinary
lead origi.`.atesf.om plasa lead'that:has been filtered.at the glomerular level; thus urinary lead
adjusted ortglomerular ftration rate seres asa proy for plasma.led levels. In this invtiga-
tion we examined the interrelationships of lead levels in whole blood by hematocrit
[i.e., erythrocyte lead (EPb)], trabecular bone (TBoP) corticalbone (CBoPb) and urneexcret-
ed oer 24 hr (UPb); all samples were obtained from 71 middle-aged n ederly men with no
known occupational lad eosures. Lead s masured by graphite furnace aomic abspion
spectroscopy (blood), K-X-ray fluorescence (bone), and inductively couple plasma mass spec-
troscopy (urine). Lead levels were generalclyQlow,.wit mean EPb, TBPb ad CBoPb values of
13.8, 31.1, and 21.7 pg/g, respectivly, tand a median UPb:vle of6.15 p/day. In generalized
additive modelsadjusted foAr bodyweight and creatiine cearance rate, both EPb and bone lead
variables remained independenly ad sgnificantly ssociated with UPb. This finding suggests
that boneinfluences pla la in a manner tt is independent ofteinfluenceoferythroytic
lead on plasma lad. Thus, th superiority ofbone lead ove bloodlead in predicting some
chronic forms oftoxic'it may b mediate through bone's influence on plasmalead. Inaddition,
this:study suggests that measurement ofurinarylead might b usef a a proxy for plasma lead
levels in studies ofl toxicity. Key work blood, bone, environmen.tai epoure, KX-.rayfluo-
rescencelead, urie. nvon HeaihPerspen 107:391-396 (1999). [Online 6April 1999]
hap//lehpnerl.inie/s.nih.govdocsu9991 07p391-396ssi/19abstrc h1tml9
Although blood levels oflead have traditional-
ly been used as a marker oflead dose in stud-
ies on the adverse effects of lead exposure,
more than 99% oflead in blood is bound to
erythrocytes (1-4). Plasma lead, the most tox-
icologically active component, is difficult to
measure accurately because levels are extreme-
ly low and may be affected by contamination
from hemolysis, sampling, and laboratory
handling (3,5,6). The skeleton is the predom-
inant endogenous storage site for lead; it con-
tains more than 95% of the total amount
stored (7-9). Lead stored in trabecular and
cortical bone has a biological half life of >1
year and >5-10 years, respectively (10-12);
thus, bone lead (especially lead in cortical
bone) has been considered a proxy for cumu-
lative exposure to lead (13-17). There is a
growing awareness that bone lead is also the
major endogenous source of lead (9,12,
14,17-27). The release of lead from bone
into the blood circulation is probably height-
ened during increased bone turnover, such as
that associated with the rapid growth ofchild-
hood (28,29), pregnancy and lactation
(30-34), menopausal osteoporosis (35,36),
hyperthyroidism (37), and pathological states
(38). Therefore, blood lead levels not only
serve as an indicator of recent environmental
exposure, but also may reflect exposure from
internal sources, primarily bone lead.
Despite the recent decline in environ-
mental and occupational lead exposure in
most developed countries (mainly due to
the removal of lead from gasoline and the
control oflead exposure in the workplace),
general exposure to low doses of lead and
pockets ofhigh lead exposure are still com-
mon in the United States (39). With the
development of in vivo K-X-ray fluores-
cence (KXRF) instruments, measurement
ofbone lead levels as an indicator ofcumu-
lative lead exposure in epidemiologic stud-
ies is now possible. Bone lead was found to
be a better biomarker of lead dose than
blood lead in recent studies ofthe relation-
ship of low-level lead exposure to hyper-
tension (40,41) and low birth weight (42).
This finding raises concerns that blood
lead levels not only inadequately represent
levels oflead accumulated in bone but also
inadequately represent levels of lead in
plasma (the primary source of bioavailable
lead to most body organs) and concerns
that bone lead stores may independently
influence plasma lead levels. Some kinetic
models as well as empirical observations
(43,44) have suggested the possibility ofan
independent contribution of bone lead to
plasma lead. More information is needed
about the extent to which lead is mobilized
out of bone in environmentally exposed
individuals.
Although plasma lead provides critical
information on the understanding of lead
mobilization from bone, it is difficult to
measure accurately. Urinary lead is an alter-
native to plasma lead. Urinary lead origi-
nates from plasma lead that has been fil-
tered at the glomerular level; thus, urinary
levels oflead that are adjusted for glomeru-
lar filtration rate serve as a proxy for plasma
lead levels.
In this study, we test the hypothesis that
bone and erythrocyte lead make indepen-
dent contributions to urine lead by examin-
ing the interrelationships of lead levels in
whole blood corrected by hematocrit [i.e.,
erythrocyte lead (EPb)], patella (TBoPb),
tibia (CBoPb), and urine excreted over 24
hr (UPb) in a group of middle-aged and
elderly men with no known occupational
lead exposure. All research was approved by
the Human Research committees of
Brigham and Women's Hospital (Boston,
MA) and the Department of Veterans
Affairs Outpatient Clinic (Boston, MA).
Methods
Study population. Study participants were
from the Normative Aging Study (NAS), a
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longitudinal study ofaging established by the
Veterans Administration in 1961 (45). The
study cohort initially consisted of2,280 men
from the Greater Boston, Massachusetts,
area. The men were 21-80 years of age
upon enrollment. All participants in the
study were free of known chronic medical
conditions at the time of enrollment; par-
ticipants were excluded ifthey had any his-
tory of cancer, recurrent asthma, sinusitis,
bronchitis, diabetes, gout, or peptic ulcer.
Those with either a systolic blood pressure
of >140 mmHg or a diastolic blood pres-
sure of >90 mmHg were also disqualified.
Since their enrollment in 1961-1968, par-
ticipants have been reevaluated at 3- to 5-
year intervals by a detailed core examina-
tion including collection ofmedical history
information, routine physical examina-
tions, laboratory tests, and questionnaires.
Since February 1987, each NAS partici-
pant has contributed a 24-hr urine speci-
men at his regularly scheduled examination.
In addition, a blood sample used only for
lead analysis has been collected at each visit
since July 1988. Beginning in August 1991,
NAS participants were recruited for a sub-
study of KXRF bone lead measurements.
Written informed consent was obtained
from all participants.
In the present study, we randomly
selected 100 men for lead analysis of 24-hr
urine specimens, using a stratified sampling
procedure based on quartiles of patella lead
distribution among those NAS subjects who
participated in the KXRF bone lead sub-
study and provided 24-hr urine specimens.
Blood lead. Blood samples were
obtained and analyzed for lead by graphite
furnace atomic absorption with Zeeman
background correction (ESA Laboratories,
Chelmsford, MA). Values below the mini-
mum detectable limit of 1 pg/dl were coded
"0." The instrument was calibrated with
National Institute of Standards and
Technology Standard Reference Material
(NIST SRM 955a; lead in blood) after every
20 samples. Ten percent of samples were
run in duplicate; at least 10% ofthe analyses
were controls and 10% were blanks. In tests
on reference samples from the Centers for
Disease Control and Prevention (Atlanta,
GA), precision [coefficient of variation
(CV)] ranged from 8% for concentrations
from 10 to 30 pg/dl to 1% for higher con-
centrations. As compared to a NIST target
of 5.7 pg/dl, 24 measurements by this
method gave a mean ± standard deviation
(SD) of5.3 + 1.23 pg/dl.
Bone lead. Bone lead was measured in
each subject's midtibia shaft and patella
with a KXRF instrument (ABIOMED,
Inc., Danvers, MA). The tibia and patella
have been targeted for bone lead research
because these two sites are considered repre-
sentative of the two main bone compart-
ments cortical and trabecular bone,
respectively. A technical description and the
validity specifications of this instrument
have been published elsewhere (46,47).
Radiation doses are minimal, with effective
doses being a fraction of those associated
with standard radiographs (48). This KXRF
instrument uses 109Cd to provoke the emis-
sion of fluorescent photons from target tis-
sue that are then detected, counted, and
arrayed on a spectrum (46). The net lead
signal is determined after subtraction of
Compton background counts by a linear
least-squares algorithm. The lead fluores-
cence signal is then normalized to the elastic
or coherently scattered 7-ray signal, which
arises predominantly from the calcium and
phosphorus present in bone mineral. The
unit of measurement so derived is micro-
grams of lead per gram of bone mineral
(micrograms per gram).
Since the inception of this study in
1991, KXRF instrument design has
improved with the adoption of a 30-mCi
'9Cd spot-source design and 1800 backscat-
ter geometry (49,50). Improvements have
also been made in the calibration of the
original KXRF instrument used for this
study. Furthermore, the original instrument
is only slightly less precise than the newer
instruments. For example, 10 repeated mea-
surements ofan 11.6-pg/g calibration phan-
tom in water (which stimulates the in vivo
situation) by our original KXRF instrument
and a 30-mCi '09Cd spot-source instrument
gave mean ± SD results of 9.2 ± 3.7 and
10.0 ± 3.3 pg/g, respectively (50). Thus, we
continued to use our original instrument to
preserve the comparability of all measure-
ments. Every week, a 10-jg/g phantom
[true concentration verified by inductively
coupled plasma mass spectrometry; see Aro
et al. (50)] was positioned and measured
10 consecutive times overnight as a first-
order calibration check; analysis of means
and SDs did not disclose any significant
shift in accuracy or precision during the life
ofthis study.
Because the instrument provides a con-
tinuous unbiased point estimate that oscil-
lates around the true bone lead value, nega-
tive point estimates are sometimes pro-
duced when the true bone lead value is
close to 0. The instrument also provides an
estimate of the uncertainty associated with
each measurement that is obtained by a
counting statistic modified by the gQodness-
of-fit for the curve function used to strip
lead fluorescent peak counts from the
underlying background. It is equivalent to a
single SD if multiple measurements are
taken. Although a minimum detectable
limit calculation oftwice this value has been
proposed for interpreting an individual's
bone lead estimate (49), retention of all
point estimates makes better use ofthe data
in epidemiological studies (51). The techni-
cians measuring bone lead were blinded to
the participants' health status.
Urinary lead. One week before his
scheduled medical examination, each par-
ticipant received a 4-liter container by mail
for 24-hr urine collection at home. Five
representative containers from each batch
of 100 urinary containers were prechecked
for lead concentration (no lead was found).
Each container was accompanied by
instructions and a questionnaire about the
collection of the sample, including time of
collection, missed collections, spillage, and
subject's use of medication. Collection
began after the first void of the morning
and continued through the first void ofthe
subsequent morning. Urine samples were
collected in the presence of an antioxidant
(3 ml sodium metabisulfite) and an acid (15
ml, 6 M hydrochloric acid) to achieve a pH
between 2 and 3. The concentration oflead
in sodium metabisulfite and in HCI has
been measured by our laboratory; values of
0.076 and 0.077 ng/ml, respectively, were
found. The total amount of lead contami-
nation from HCI and metabisulfite was
1.37 ng. Contamination was insignificant
based on the lowest amount of lead mea-
sured in urine (0.73 pg). The samples were
stored at -200C before assay, then thawed,
aliquotted, digested with HNO3at roonm
temperature, and analyzed by inductively
coupled plasma mass spectrometry (Sciex
Elan 5000, Perkin-Elmer, Norwalk, CT)
with standard instrument-operating and
data-collecting parameters using the isotope
dilution procedure (52). Prior to analysis,
the mass spectrometer setting and nebulizer
flow rate were optimized to give maximum
peak intensity for lead. A solution (10
ng/ml) of enriched isotope spike (206Pb;
NIST SRM 983) was mixed with the sam-
ple online by means of a mixing Tee and a
mixing coil. Data were expressed as the
average offive replicate measurements. The
accuracy of the isotope dilution procedure
has been verified using urine samples from
interlaboratory comparison study samples
from the Quebec Interlaboratory
Comparison Program (Le Center de
Toxicologe du Quebec), whose target values
were determined by electrothermal atomic
absorption spectroscopy. The percentage
error calculated for Pb determination in
urine samples ranged from -4.26 to 2.6%.
Quality control and quality assurance
procedures included analyses of procedural
blanks to monitor contamination and
NIST SRM 2670e (toxic elements in urine)
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to monitor the accuracy and recovery rates
for each analytic batch. The concentration
in the procedural blanks was 0.03 ng/ml
with a detection limit of 0.02 ng/ml.
Recovery ofthese quality control standards
is between 95 and 105%, and the precision
(relative standard deviation) of the Pb
determination is approximately 1%.
Creatinine. We used the Beckman
Creatinine Analyzer 2 (Beckman, Brea,
CA) to measure creatinine in serump and in
archived (frozen) 24-hr urine samples by
routine laboratory method Uaffe method).
This method of analysis has a detection
limit of 0.2 mg/dl with intra-assay CV of
2.4% at 17.7 mg/dl and inter-assay CV of
3.1% at 17.6 mg/dl.
Statistical analysis. Any 24-hr urine
sample with a volume of<750 ml or with a
collection time of<20 hrwas excluded from
this analysis to ensure quality. We estimated
glomerular flow rate from the clearance rate
of endogenously produced creatinine.
Creatinine dearance rate (CCr) was calcu-
lated by the following formula: CCr
(ml/min) = [total amount ofurinary creati-
nine over 24 hr (mg)]/[serum creatinine
concentration (mg/ml) x collection time
(min)]. Lead in blood is composed of two
parts-bound to red blood cell (erythro-
cyte) and free in plasma. Because more than
99% of lead in whole blood is bound to
erythrocytes (3,4), the part ofplasma lead is
negligible and whole blood lead (BPb) con-
centration can be inferred as the approxi-
mate of erythrocyte lead (EPb) concentra-
tion weighted by the percentage of blood
volume occupied by erythrocytes, i.e., BPb
- EPb x hematocrit. Therefore, EPb con-
centration was calculated by the following
formula: EPb (pg/dl) = [whole blood lead
concentration (ggldl)]/[hematocrit (%)].
The relationship between blood lead and
plasma lead is nonlinear at blood lead levels
of >40 pg/dl in adults (3,4). The relation
Table 1. Lead levels in whole blood, erythrocytes,
bone, and 24-hr urine from 71 middle-aged and
elderly men inthe Normative Aging Study
Variable Mean ± SD Range
Age (years) 67.77 ± 6.1 53.01-81.67
Bodyweight(kg) 85.42 ±13.4 59.47-128.03
Creatinine clearance 91.73 + 25.7 55.18-162.92
rate (ml/min)
Whole blood 5.94 ± 3.0 0.00-15.00
lead (pg/dl)
Erythrocyte 13.81 ± 7.0 0.00-35.90
lead (pg/dl)a
Patella lead (pg/g) 31.1 ± 15.1 6.0-74.0
Tibia lead (pg/g) 21.7 ± 10.9 5.0-49.0
Urinary lead (pg/day) 5.69(1.9)b 0.73-19.57
SD, standard deviation.
°Erythrocyte lead calculated bydividing whole blood lead by
hematocritvalues.
bGeometric mean.
between blood lead and urinary lead among
lead workers is also nonlinear, according to a
recentstudy (43). Little has been reported on
those relationships in nonoccupationally
exposed individuals. A recent study on envi-
ronmentally exposed individuals reported a
poor linear relationship between blood lead
and urine lead, particularly at lower range of
exposures (53). It was considered possible
that the relation between blood lead and uri-
nary lead would be nonlinear in the popula-
tion we studied. Before we examined the
independent contribution of bone lead to
urinary lead, we needed to control for possi-
ble nonlinearities in their relationship. One
analytical methodwell suited to such ataskis
thegeneralized additive model (GAM) (54).
A standard linear regression model
assumes thatE(Y) = 00 +PIX, + ... + p1X1,
where E(Y) denotes the expectedvalue of
and the predictor variables (Xl-X) may be
transforms ofunderlying variables or prod-
ucts of those variables. Although this
approach can incorporate nonlinear forms
ofthe dependencies, it is necessary to speci-
fy the functional form of those dependen-
cies. If we believe we know the correct
covariates but not necessarily the correct
functional forms, the GAM offers a non-
parametric regression alternative. It assumes
that EY) =P +S,(Xj) + ... + Sp(X).
In this case, S,(X,) is a smooth function
ofX, that is fit nonparametrically. A non-
parametric smoother is a tool forsummariz-
ing the trend ofa response measurement Y
as a function ofone or more predictor mea-
surements. Most smoothers are generaliza-
tions ofweighted moving averages. These
predict the expected value of Yat Xk as the
weighted mean ofthe values ofthe Y,corre-
sponding to all theX,in a symmetric neigh-
borhood around Xk. The weights decline
with distance from the center ofthe neigh-
borhood. The properties ofmoving average
smoothers have been extensively discussed
(55,56) and the utility of GAMs for envi-
ronmental epidemiologic studies has been
well demonstrated (57-59). Linear terms
are a special subset ofsmoothers, and linear
variables can be mixed with nonparametric
smoothers in this model. This approach not
only offers descriptive advantages, but also
is of value as an adjustment tool in the
determination of an effect of interest. As a
visual summary, the smoother is helpful
and maysuggestpossible parametric forms.
The loess smoothed parameter (60) was
used in this analysiswith selection ofapara-
meter that minimizes Aikaike's information
criterion (61). Twenty-four-hour urinary
lead was regressed on smooth functions of
age, EPb, CCr, and bodyweight. We chose
the best smoothing parameter for each vari-
able in models that did not contain bone
lead variables. Patella lead and tibia lead
were then examined to see whether they
made any independent contribution to 24-
hr urinary lead levels. Only subjects with
complete data sets were included in the
analysis, and all regressions were estimated
in S-pluswith the GAM function.
Results
Two subjects with missing data on EPb
and urinary creatinine were eliminated
from the analysis, as were four subjects
with 24-hr urine volume of <750 ml or
with <20 hr of urine collecting time. In
addition, 17 subjects with reduced renal
function (a serum creatinine concentration
of >1.5 mg/dl or a CCr of <50 ml/min)
were excluded. Generalized ESD many-
outlier procedures (62) were run on the
remaining 77 subjects. Six subjects, who
had an EPb of>47 pg/dl, a TBoPb of>90
pg/dl, or a body weight of >130 kg, were
identified as outliers. After these outliers
were excluded, 71 subjects remained for
regression analysis. The means, SDs, and
ranges for the variables ofinterest are listed
in Table 1, and Spearman correlations are
summarized in Table 2. TBoPb is signifi-
cantly higher than CBoPb. EPb had the
strongest correlation with UPb, followed
byCCr, TBoPb, and CBoPb. TBoPb was a
stronger correlate ofEPb than was CBoPb.
UPb was positively correlated with CCr,
probably because the amount of lead
excreted into urine is modified by renal
function. Body weight was negatively cor-
related with TBoPb and CBoPb and was
positively correlated with CCr and UPb.
Table 2. Spearman correlations between biological markers of lead dose, age, and creatinine clearance
inthe 71 middle-aged and elderly men inthe Normative Aging Study
Creatinine
Erythrocyte Patella Tibia clearance Body
Variable Age lead lead lead rate weight
Urinary lead 0.077 0.673** 0.347** 0.278** 0.514** 0.053
Age 0.071 0.126 0.208 -0.152 -0.176
Erythrocyte lead 0.362** 0.251* 0.217 0.136
Patella lead 0.694** -0.037 -0.287
Tibia lead 0.038 -0.279*
Creatinine clearance rate 0.250*
*p<0.05;**p<0.01.
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Neither a linear term nor a smooth
function ofage was a significant predictor of
UPb. Moreover, the model fit was the same
with or without age. Age was therefore
dropped from these models. A GAM plot
showed a somewhat nonlinear EPb-UPb
relationship after adjustment for CCr and
body weight (Fig. 1). After adjustment for
EPb, CCr, and body weight, TBoPb and
CBoPb were significant predictors of UPb
in separate models. According to Aikaike's
information criterion (61), CBoPb fit as
well as TBoPb. GAM plots from both mod-
els indicated that lead stored in these two
bone sites had different relations with UPb.
The TBoPb-UPb relation was linear ( =
0.05) (Fig. 2) and the mean contribution of
lead from trabecular bone to urine was 1.6
pg/day. In contrast, the CBoPb-UPb rela-
tion was linear only above a threshold of24
pg/g, and no CBoPb-UPb association was
evident at CBoPb values below 24 pg/g.
Only 38% of the subjects had CBoPb >24
pg/g. On the basis ofthis finding, we took a
different approach and refit the tibia lead
model. Because of the observed threshold
effect of tibia lead on UPb, a new variable
was introduced to replace the loess function
of tibia lead. This new variable, hightib, has
a value of0 ifCBoPb is <24 and has a value
ofCBoPb-24 otherwise. The results are list-
ed in Table 3. The model with a linear term
ofhightib (3 = 0.12) fit as well as the patella
lead model. Mean contribution oflead from
cortical bone to urine was 0.43 pg/day. The
nonlinear EPB-UPb relation remained sig-
nificant in both the patella lead and new
tibia lead models.
Discussion
The results of the present study indicate a
strong nonlinear relation of EPb to UPb as
well as an independent association ofskele-
tal lead to UPb. After adjustment for EPb,
CCr, and body weight, TBoPb and CBoPb
were significant predictors of UPb in sepa-
rate models.
The middle-aged and elderly male
participants in this study had no known
occupational exposure to lead, and their
environmental exposures to lead were pre-
sumably through contaminated drinking
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Figure 1. The smoothed relationship of erythrocyte lead to urinary lead after adjustment for smoothed
terms of creatinine clearance and bodyweight.
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Figure 2. The relationship of patella lead to urinary lead after adjustment for smoothed terms of erythro-
cyte lead, creatinine clearance, and body weight.
water, air, and food. A simple kinetic model
of lead in the body can be described as
equilibrium between bone and blood.
However, in this study population, skeletal
stores may be the source of increased levels
of lead circulating in plasma and therefore
ofincreased lead excretion in urine because
of increased bone mineral loss resulting
from aging (Fig. 3). The significant inde-
pendent relations of UPb with bone lead,
which we observed in the GAM, is consis-
tent with the potential role of the skeleton
as an important endogenous source oflabile
lead that may not be adequately discerned
by examining whole blood lead or EPb.
The direct evidence of contribution of lead
from skeleton to urine and to blood has
been shown by lead tracer methods (12,63)
and stable isotope methods (25,64,65),
respectively. The stable lead isotope method
has the ability to distinguish between lead
from endogenous sources (i.e., skeleton)
and from dietary sources. Forty-one to 73%
of blood lead originated from bone in a
group of adult women (25), as opposed to
20% of total blood attributable to bone
lead in a nonhuman primate (64). A recent
study of nonhuman primates using the
same technique observed a significant
increase in bone-derived lead in maternal
blood in late pregnancy (65).
Bone lead turnover is determined by
lead exchange at bone surfaces and factors
affecting bone remodeling (66,617).
Trabecular bone has a larger surface area
and a greater volume ofblood delivered per
unit of time than cortical bone. In addi-
tion, there are more active osteons per
gram in trabecular bone to carry out
resorption and deposition than in cortical
bone. Consequently, endogenous exposure
would be expected to relate more closely to
trabecular than to cortical lead, and trabec-
ular bone would be expected to relate more
closely to circulating lead and urinary lead.
Our findings that TBoPb was a stronger
correlate ofEPb and UPb than was CBoPb
(Table 2) and contributed more lead in
urine (1.6 pg/day from TBoPb and 0.43
pg/day from CBoPb) are consistent with
these ideas. Similar findings regarding the
blood lead-trabecular bone lead association
Table 3. Generalized additive models relating
bone lead measures to urine leada
Coefficient SE
Tibia lead model
Tibia lead 0.12* 0.05
Patella lead model
Patella lead 0.05* 0.02
SE, standard error.
aEach model adjusts for smooth functions of hematocrit-adjusted
blood lead, body weight, and creatinine clearance.
*p<0.05.
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Figure 3. Conceptual model of plasma lead exchange in the human body.
have been reported in a previous cross-sec-
tional study in the NAS population (68)
and in a case-control study ofpostpartum
women in Mexico City (69). In addition, a
recent study reported that bone lead (par-
ticularly trabecular bone lead) exerts an
additional independent influence on plas-
ma lead after controlling for whole blood
lead in individuals with no history ofoccu-
pational lead exposure (70). Together,
these findings support the argument that
lead in trabecular bone is more available for
mobilization and has more influence on
the amount of lead excreted in urine than
in cortical bone.
As depicted in Figure 3, lead in blood is
divided between erythrocyte and plasma
compartments. Although the lead-binding
capacity of erythrocytes is usually assumed
to have specific limits (71), factors govern-
ing the relative partitioning between lead in
plasma and erythrocyte are not well known.
Marcus (71) points out the existence of
other possible models in addition to the sat-
uration model. Leggett (29) also notes that
the saturation concentration may depend on
the levels and duration of exposure. Bone
lead is an important endogenous source of
plasma lead, whereas whole blood lead is an
important determinant ofplasma lead (Fig.
3). Cake et al. (72 noted that among active
workers in a lead recycling facility, the
serum/blood lead ratio correlated signifi-
cantly and positively with bone lead but not
with whole blood lead. They hypothesized
that part of the variation in serum/blood
lead ratio could be attributed to lead
released from bone and therefore high bone
lead levels produce high serum/blood lead
ratios. Berghdahl and Skerfving's (73) recent
observation among retired lead smelter
workers undermined the hypothesis pro-
posed by Cake et al. (72). However, the
finding of a significant correlation of plas-
ma/blood ratio to blood and bone lead in
environmentally exposed adults (70) is in
good agreement with the Cake et al. (72)
hypothesis. Discrepancies between these
studies might be explained by the use ofdif-
ferent target sites for bone lead measurement
and different leadexposure levels.
In contrast, there are few reports on the
relationships ofBPb or PPb to UPb. Most
ofthe observations were collected on occu-
pationally exposed individuals. The rela-
tionship between BPb and UPb among
lead workers was nonlinear in a recent
study (43). Hirata et al. (44) noted that the
correlation between the concentrations of
PPb and ofUPb exceeded that between the
concentrations of BPb and UPb among
lead workers with low levels of lead expo-
sure. A physiologically based kinetic model
predicted that the rate of lead excretion
into urine is directly proportional to plas-
ma concentration (66). Only one observa-
tion of the BPb-UPb relationship among
environmentally exposed individuals is
available (53). The authors noted a poor
linear relationship between BPb and UPb,
particularly at lower range of exposures
(53). Although we were unable to directly
investigate the relationship between UPb
and PPb, the curvilinear relation (Fig. 1)
and strong correlation between UPb and
EPb in the present study are compatible
with the findings of a nonlinear relation-
ship as seen in previous studies.
The main source ofexternal exposure to
lead includes diet and air for individuals
without occupational exposure. Tap water in
a city like Boston, with old houses contain-
ing lead plumbing, is a significant dietary
source ofpotential lead exposure. The mean
whole blood lead levels in the NAS popula-
tion is representative of the general popula-
tion in the United States (74). A recentstudy
in a subset of the NAS population found
that ingestion of lead-contaminated tap
water is an important predictor of elevated
bone lead levels later in life (75). Lead in
diet, in addition to bone lead and blood
lead, may contribute substantially to lead in
urine. Our study was limited by the fact
that dietary intake oflead was not measured
and we were unable to distinguish between
lead from the skeleton and lead from
dietary sources. Nevertheless, in an aging
population like the NAS, where endoge-
nous exposure is the dominant contributor
to whole blood lead, the influence of diet
should be minimal.
Glomerular function, in addition to
bone lead and EPb, is another critical deter-
minant of the amount of lead excreted.
Because it is possible that renal impairment
influences lead levels in blood and urine, we
excluded all subjects with significant renal
impairment (serum creatinine levels of.1.5
mg/dl or a CCr of<50 ml/min) and we fur-
ther controlled for renal function by includ-
ing the best smooth function ofCCr in our
models. Accordingly, it is unlikely that our
results were significantly influenced by renal
impairment.
In summary, our findings of indepen-
dent contributions ofbone and erythrocyte
lead to urine lead indicate that the skeleton
is an important endogenous source oflead
exposure in environmentally exposed sub-
jects. Moreover, UPb originating from PPb
may be an alternative measure ofthe most
metabolically relevant fraction of lead in
blood that will be useful in assessing the
potential hazard in populations where
endogenous exposure is the dominant con-
tributor to whole blood lead. Further
research is needed to examine the use of
UPb as an alternative to PPb in examining
the mechanism of bone lead toxicity in
environmentally exposed subjects.
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